Project type
EPCMV contract
Client
Client confidential
Investment sum
CHF 30 million
Planning / implementation period
2018 - 2021
Project description
Planning and execution of a mono & a multi production plant for the production of antibody drug conjugates (ADC). The production must be able to be operated safely in the OEL range ≤1ng/m3. The two plants are planned in an existing building, whereby the mono plant is to be prioritized, i.e. the multi plant is to be completed while the mono plant is still in operation.
pixon engineering was entrusted with the delivery of the entire project from the basic design onwards as part of an EPCMV contract excluding automation.
Activities:
Project Challenge
The very high installation density of the infrastructure required a great deal of planning skill. In addition to the complex process requirements, particular attention was paid to accessibility for maintenance. Due to the highly toxic production, the process (containment) and the entire infrastructure had to be planned in compliance with the OEL range ≤1ng/m3. In the second stage (multi-plant), the ongoing production of the mono plant poses a further difficulty in not influencing it. Some areas are used by both plants.